samedan logo

 
 
spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

Axol Bioscience introduces multi-electrode array screening services for human iPSC-derived cells

Axol Bioscience


• Expansion of Axol Bioscience’s service offering for pre-clinical drug discovery
• New services combine the Company’s iPSC-derived human cells and electrophysiological expertise with Axion Biosystems’ Maestro Pro MEA platform

Cambridge, UK, 13 October 2020: Axol Bioscience (Axol), a biotechnology company specializing in the use of stem cell technology to manufacture disease-relevant cell-based assay systems to the drug discovery industry, today announced the expansion of its service offering, with the introduction of multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells. The new services have been developed to support pre-clinical research by optimizing hiPSC-derived cell culture, while providing high-quality electrophysiological data acquisition and analysis from physiologically relevant human cell models.

As part of the new services, Axol is incorporating the Maestro Pro, a market-leading MEA platform from Axion Biosystems (Axion). This will allow customers to benefit from Axol’s extensive catalog of hiPSC-derived cells and in-house electrophysiology expertise, in combination with Axion’s most advanced offering. The Maestro Pro enables continuous label-free and real-time data acquisition and analysis from 768 electrodes, in up to a 96wp format, allowing for a high-throughput of data.

Axol’s MEA screening service offering will include:
• recording of field action potentials from neurons and cardiomyocytes
• local extracellular action potential (LEAP) and contractility recordings from cardiomyocytes
• cell visualization and multiplexing for microscopy and calcium imaging assays
• targeted panel compound and new chemical entity (NCE) screening
• cardiotoxicity and neurotoxicity testing
• cell, co-culture and disease model validation
• long-term cell proliferation studies
• bespoke projects and pilot studies.

The launch of Axol’s services follows the recent appointment of Liam Taylor as CEO at Axol, and forms part of the Company’s strategy to grow its iPSC technologies, products and services.

Liam Taylor, CEO, Axol Bioscience, said:“At Axol, we have worked extremely hard to establish ourselves as the market-leading provider of neuroscience and cardio-based hiPSC-derived cells. As we grow, it's now time to also offer our considerable in-house expertise to the preclinical drug discovery market. As such, we are proud to announce our new MEA capability utilizing the industry-leading Axion Maestro Pro platform.”

For further information about Axol’s MEA screening services, please visit: https://www.axolbio.com/page/mea-services
phone +44 (0)1223 751051
email support@axolbio.com
web https://www.axolbio.com/
email Suite 3, The Science Village, Chesterford Research Park, Little Chesterford, Cambridgeshire, CB10 1XL, United Kingdom
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETOT (pralsetinib)

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
More info >>


White Papers

Transforming Temperature Data Management Practices to Reduce Labor Costs and Improve Visibility and Control

Berlinger & Co AG

There are a number of temperature monitoring database options available to the biopharma supply chain professional and choosing the right one can significantly improve workflow which will reduce administrative time. This article will provide insight into practices for improving common processes through enhanced database functionality in the areas of managing data loggers by expiry date, storing and retrieving calibration certificates and acknowledging/documenting common temperature excursion events. Additionally, it describes the unique features and benefits of the Berlinger Smartview® data management system. Smartview® is a “Software as a Service” (SaaS) platform designed to efficiently and accurately manage both workflow and data in a regulatory compliant manner (21 CRF Part 11 & Annex 11). This comprehensive temperature data management system ensures reliability, accuracy, security, accessibility, and visibility to supply chain professionals, enhancing Good Distribution Practices (GDP) of temperature sensitive shipments.
More info >>

Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement